Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)
September 12, 2022 07:00 ET
|
Alector, Inc.
AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies...
Alector to Participate in Upcoming Healthcare Conferences
September 07, 2022 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022 16:05 ET
|
Alector, Inc.
Investigational New Drug Application submitted for AL044, a novel drug candidate targeting an Alzheimer’s disease risk gene Expanding clinical sites to drive additional enrollment in the INFRONT-3...
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
May 27, 2022 16:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation...
Alector Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 16:05 ET
|
Alector, Inc.
Data from INFRONT-2 Phase 2 clinical trial showed that FTD-C9orf72 patients treated with AL001 (latozinemab) demonstrated a trend towards an annual delay in disease progression of approximately 54...
Alector to Participate at the BofA Securities 2022 Healthcare Conference
May 04, 2022 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer
March 29, 2022 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of...
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
March 15, 2022 08:00 ET
|
Alector, Inc.
Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated with latozinemab demonstrated a trend...
Alector to Present at Upcoming Healthcare Conferences
March 09, 2022 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...